Article info

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Authors

  • Tina Baker Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Hoda Sharifian Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden PubMed articlesGoogle scholar articles
  • Paul J Newcombe Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Patrick G Gavin Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Mark N Lazarus Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Madhu Ramaswamy Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Wendy I White Clinical & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Nicola Ferrari Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Daniel Muthas Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden PubMed articlesGoogle scholar articles
  • Raj Tummala Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Eric F Morand Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Richard A Furie Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA PubMed articlesGoogle scholar articles
  • Edward M Vital Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK PubMed articlesGoogle scholar articles
  • Chris Chamberlain Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Adam Platt Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  • Hussein Al-Mossawi Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Philip Z Brohawn Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA PubMed articlesGoogle scholar articles
  • Eszter Csomor Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Eszter Csomor, Translational Science & Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca R&D, Cambridge, UK; eszter.csomor{at}astrazeneca.com
View Full Text

Citation

Baker T, Sharifian H, Newcombe PJ, et al
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Publication history

  • Received December 20, 2023
  • Accepted March 21, 2024
  • First published April 3, 2024.
Online issue publication 
July 15, 2024

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.